PMID- 21521283 OWN - NLM STAT- MEDLINE DCOM- 20150209 LR - 20220310 IS - 1365-2265 (Electronic) IS - 0300-0664 (Print) IS - 0300-0664 (Linking) VI - 75 IP - 1 DP - 2011 Jul TI - Durability of the effects of testosterone and growth hormone supplementation in older community-dwelling men: the HORMA Trial. PG - 103-11 LID - 10.1111/j.1365-2265.2011.04014.x [doi] AB - OBJECTIVES: To determine the durability of anabolic effects and adverse events (AEs) after stopping testosterone and growth hormone supplementation in older men. DESIGN: Secondary analysis of a double-masked, randomized controlled trial of testosterone gel (5 or 10 g/daily) plus rhGH (0, 3 or 5 mug/kg/day) with follow-up of outcomes 3 months later. PARTICIPANTS: A total of 108 community-dwelling 65- to 90-year-old men. MEASUREMENTS: Testosterone and IGF-1 levels, body composition (DEXA), 1-repetition maximum (1-RM) strength, stair-climbing power, quality-of-life (QOL) and activity questionnaires, AEs. RESULTS: Despite improvements in body composition during treatment, residual benefits 3 months later (week 28) were variable. For participants with improvements exceeding their week-17 median changes, benefits were sustained at week 28 for lean body mass (1.45 +/- 1.63 kg, 45% of week-17 values, P < 0.0001 vs baseline), appendicular skeletal muscle mass (ASMM, 0.71 +/- 1.01 kg, 42%, P < 0.0001), total fat (-1.06 +/- 2.18 kg, 40%, P < 0.0001) and trunk fat (-0.89 +/- 1.42 kg, 50%, P < 0.0001); retention of ASMM was associated with greater week-16 protein intake (P = 0.01). For 1-RM strength, 39%-43% of week-17 improvements (P